Treatment Information

Cancer Monthly > Treatment Information
Back

Ovarian Cancer treatment details. Immunotherapy.

Vaccine Branch, CCR, NCI, Bethesda, MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Bethesda, MD
Treatments:ImmunotherapyHospital:Vaccine Branch, CCR, NCI
Drugs:Journal:Link
Date:Sep 2011

Description:

Patients:
This study involved women with ovarian cancer and overexpression of the p53 gene. It was noted that there was no evidence of disease in the patients at the beginning of the study. Patients were divided into 2 separate treatment groups. Group A had 14 patients with a median age of 57 years and group B had 7 patients with a median age of 54 years.

Treatment:
Group A was treated with the biologic agent GM-CSF and a subcutaneous peptide vaccine that contained parts of the p53 protein.

Group B was treated with an intravenous injection of their own immune cells (dendritic cells) that had been previously collected and treated with parts of the p53 protein so that the cells would cause an immune reaction to the protein in the body.

Toxicities:
The maximum toxicity reported for group A was of grade 4, including grade 3/4 increased liver enzymes, fatigue, and joint pain. The maximum toxicity reported for group B was also of grade 4, including grade 3/4 increased lymphopenia, fatigue, and fever.

Results:
The median overall survival for groups A and B was 40.8 and 29.6 months, respectively.

Correspondence: Dr. Samir N. Khleif; email: [email protected]

Email Physician More Information


Back